| Characteristic . | HR . | 95% CI . | P Value . |
|---|---|---|---|
| Adherence to forecast | |||
| ON TIME_BOTH INF3_INF4 | — | — | |
| LATE_BOTH_INF3_INF4 | 7.99 | 3.49-18.3 | <.001 |
| LATE_INF3_ON TIME_INF4 | 1.98 | 0.82-4.80 | .13 |
| ON TIME INF3_LATE INF4 | 2.37 | 1.18-4.77 | .02 |
| Sex | |||
| Male | — | — | |
| Female | 0.82 | 0.47-1.43 | .5 |
| Baseline age | |||
| <18 y | — | — | |
| ≥18 y | 1.55 | 0.79-3.05 | .2 |
| Weight, kg | 1.01 | 0.99-1.03 | .3 |
| Starting dose | |||
| 5 mg/kg | — | — | |
| 10 mg/kg | 0.99 | 0.55-1.79 | >.9 |
| Diagnosis | |||
| CD | — | — | |
| IBD-U | 0.00 | 0.00-∞ | >.9 |
| UC | 3.21 | 1.74-5.94 | <.001 |
| Baseline steroid | |||
| No | — | — | |
| Prednisone | 2.34 | 1.15-4.76 | .02 |
| Budesonide | 1.12 | 0.44-2.84 | .8 |
| Baseline immunomodulators | |||
| No | — | — | |
| MTX | 0.62 | 0.08-4.89 | .6 |
| 6-MP | 0.67 | 0.15-2.98 | .6 |
| AZA | 2.42 | 0.48-12.2 | .3 |
| Characteristic . | HR . | 95% CI . | P Value . |
|---|---|---|---|
| Adherence to forecast | |||
| ON TIME_BOTH INF3_INF4 | — | — | |
| LATE_BOTH_INF3_INF4 | 7.99 | 3.49-18.3 | <.001 |
| LATE_INF3_ON TIME_INF4 | 1.98 | 0.82-4.80 | .13 |
| ON TIME INF3_LATE INF4 | 2.37 | 1.18-4.77 | .02 |
| Sex | |||
| Male | — | — | |
| Female | 0.82 | 0.47-1.43 | .5 |
| Baseline age | |||
| <18 y | — | — | |
| ≥18 y | 1.55 | 0.79-3.05 | .2 |
| Weight, kg | 1.01 | 0.99-1.03 | .3 |
| Starting dose | |||
| 5 mg/kg | — | — | |
| 10 mg/kg | 0.99 | 0.55-1.79 | >.9 |
| Diagnosis | |||
| CD | — | — | |
| IBD-U | 0.00 | 0.00-∞ | >.9 |
| UC | 3.21 | 1.74-5.94 | <.001 |
| Baseline steroid | |||
| No | — | — | |
| Prednisone | 2.34 | 1.15-4.76 | .02 |
| Budesonide | 1.12 | 0.44-2.84 | .8 |
| Baseline immunomodulators | |||
| No | — | — | |
| MTX | 0.62 | 0.08-4.89 | .6 |
| 6-MP | 0.67 | 0.15-2.98 | .6 |
| AZA | 2.42 | 0.48-12.2 | .3 |
Abbreviations: 6-MP, 6-mercaptopurine; AZA, azathioprine; CD, Crohn’s disease; CI, confidence interval; HR, hazard ratio; IBD-U, inflammatory bowel disease unclassified; IFX, infliximab; MTX, methotrexate; UC, ulcerative colitis.
| Characteristic . | HR . | 95% CI . | P Value . |
|---|---|---|---|
| Adherence to forecast | |||
| ON TIME_BOTH INF3_INF4 | — | — | |
| LATE_BOTH_INF3_INF4 | 7.99 | 3.49-18.3 | <.001 |
| LATE_INF3_ON TIME_INF4 | 1.98 | 0.82-4.80 | .13 |
| ON TIME INF3_LATE INF4 | 2.37 | 1.18-4.77 | .02 |
| Sex | |||
| Male | — | — | |
| Female | 0.82 | 0.47-1.43 | .5 |
| Baseline age | |||
| <18 y | — | — | |
| ≥18 y | 1.55 | 0.79-3.05 | .2 |
| Weight, kg | 1.01 | 0.99-1.03 | .3 |
| Starting dose | |||
| 5 mg/kg | — | — | |
| 10 mg/kg | 0.99 | 0.55-1.79 | >.9 |
| Diagnosis | |||
| CD | — | — | |
| IBD-U | 0.00 | 0.00-∞ | >.9 |
| UC | 3.21 | 1.74-5.94 | <.001 |
| Baseline steroid | |||
| No | — | — | |
| Prednisone | 2.34 | 1.15-4.76 | .02 |
| Budesonide | 1.12 | 0.44-2.84 | .8 |
| Baseline immunomodulators | |||
| No | — | — | |
| MTX | 0.62 | 0.08-4.89 | .6 |
| 6-MP | 0.67 | 0.15-2.98 | .6 |
| AZA | 2.42 | 0.48-12.2 | .3 |
| Characteristic . | HR . | 95% CI . | P Value . |
|---|---|---|---|
| Adherence to forecast | |||
| ON TIME_BOTH INF3_INF4 | — | — | |
| LATE_BOTH_INF3_INF4 | 7.99 | 3.49-18.3 | <.001 |
| LATE_INF3_ON TIME_INF4 | 1.98 | 0.82-4.80 | .13 |
| ON TIME INF3_LATE INF4 | 2.37 | 1.18-4.77 | .02 |
| Sex | |||
| Male | — | — | |
| Female | 0.82 | 0.47-1.43 | .5 |
| Baseline age | |||
| <18 y | — | — | |
| ≥18 y | 1.55 | 0.79-3.05 | .2 |
| Weight, kg | 1.01 | 0.99-1.03 | .3 |
| Starting dose | |||
| 5 mg/kg | — | — | |
| 10 mg/kg | 0.99 | 0.55-1.79 | >.9 |
| Diagnosis | |||
| CD | — | — | |
| IBD-U | 0.00 | 0.00-∞ | >.9 |
| UC | 3.21 | 1.74-5.94 | <.001 |
| Baseline steroid | |||
| No | — | — | |
| Prednisone | 2.34 | 1.15-4.76 | .02 |
| Budesonide | 1.12 | 0.44-2.84 | .8 |
| Baseline immunomodulators | |||
| No | — | — | |
| MTX | 0.62 | 0.08-4.89 | .6 |
| 6-MP | 0.67 | 0.15-2.98 | .6 |
| AZA | 2.42 | 0.48-12.2 | .3 |
Abbreviations: 6-MP, 6-mercaptopurine; AZA, azathioprine; CD, Crohn’s disease; CI, confidence interval; HR, hazard ratio; IBD-U, inflammatory bowel disease unclassified; IFX, infliximab; MTX, methotrexate; UC, ulcerative colitis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
